NCT07435090

Efficacy and Safety of Rimegepant for Acute Dizziness

A Multicenter Randomized Controlled Trial on the Efficacy and Safety of Rimegepant in the Treatment of Acute Dizziness

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 370 (estimated)
• Sponsor: Shi Tianming · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore the efficacy and safety of rimegepant for acute dizziness, including vestibular migraine (VM) and benign recurrent vertigo (BRV), through a multicenter, randomized controlled clinical trial. This study addresses the urgent clinical need for effective therapies for acute dizziness. Additionally, we will dynamically observe the changes in calcitonin gene-related peptide (CGRP) levels before and after treatment and explore the predictive value of CGRP levels for treatment efficacy and the prognosis of recurrence in patients. This study aims to provide a scientific basis to improve clinical management strategies for acute dizziness.

Conditions

• Dizziness

Interventions

Type	Name	Description
DRUG	Rimegepant 75mg Orally Disintegrating Tablets (ODT)	A single dose of Rimegepant orally disintegrating tablets (75 mg) combined with betahistine mesylate (12 mg) administered orally.
DRUG	Betahistine Mesylate tablet	A single dose of betahistine mesylate (12 mg) administered orally.

Timeline

• Start date: 2026-03-20
• Primary completion: 2027-12-31
• Completion: 2028-06-30
• First posted: 2026-02-27
• Last updated: 2026-02-27